Fr. 146.00

Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America

English · Hardback

Shipping usually within 3 to 5 weeks

Description

Read more

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.

Product details

Assisted by John P Leonard (Editor), John P. Leonard (Editor), Leonard John P. (Editor)
Publisher Elsevier Health Science
 
Languages English
Product format Hardback
Released 02.09.2020
 
EAN 9780323763127
ISBN 978-0-323-76312-7
Dimensions 152 mm x 228 mm x 229 mm
Weight 500 g
Series The Clinics: Internal Medicine
Subjects Natural sciences, medicine, IT, technology > Medicine > Clinical medicine

MEDICAL / Hematology, Haematology, mantle cell lymphoma; mcl biology

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.